HI
ABCL icon

Harbour Investments’s AbCellera Biologics ABCL Stock Holding History

Harbour Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$766 Sell
98
-29
-23% -$142 ﹤0.01% 4278
2026
Q1 		$443 Buy
+127
New +$457 ﹤0.01% 4279
2021
Q4 		– Sell
-27
Closed -$1K – 2607
2021
Q3 		$1K Buy
27
+2
+8% +$35 ﹤0.01% 3418
2021
Q2 		$1K Buy
25
+20
+400% +$552 ﹤0.01% 3478
2021
Q1 		$0 Buy
+5
New +$199 ﹤0.01% 3579

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Harbour Investments's ABCL Position: Q2 2026 in Review

Harbour Investments reduced its AbCellera Biologics (ABCL) stake by 23% in Q2 2026, selling an estimated $142 and leaving 98 shares worth $766. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

Harbour Investments first reported a position in ABCL in Q1 2021 and has held it in 5 quarters since. The position peaked at $1K in Q3 2021. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Harbour Investments held 98 shares of AbCellera Biologics worth $766 as of Q2 2026.
  • Harbour Investments sold 29 AbCellera Biologics shares in Q2 2026, an estimated $142.
  • AbCellera Biologics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4278 holding.
  • Harbour Investments first reported a position in AbCellera Biologics in Q1 2021 and has held it in 5 quarters since.
  • Harbour Investments's AbCellera Biologics position peaked at $1K in Q3 2021.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.